Powder Systems Ltd's (PSL's) new GFD™ isolator combines the latest innovation to provide a high containment lab scale filtration and drying solution with the same reliability and benefits as PSL high containment production size filter dryers.
Powder Systems Ltd's (PSL's) new GFD isolator combines the latest innovation to provide a high containment lab scale filtration and drying solution with the same reliability and benefits as PSL high containment production size filter dryers.
The GFD works on a vacuum, has a heated jacket for drying and a removable filtration basket for collection of the product. The new high containment system ensures operator protection and safety for the handling of highly potent and valuable products.
The GFD is available in 3 standard sizes to fulfil the needs of any lab, kilo lab or pilot plant requirement including: MINI LAB GFD (0.002m²), LAB GFD (0.01m²) and MAXI LAB GFD (0.05m²). PSL MINI and LAB GFDs are available with high containment isolation systems.
PSL is an international manufacturer of filtration, drying and high containment isolator solutions for pharmaceutical, biopharmaceutical, chemical and laboratory industries.
PSL was established 22 years ago as an original pioneer of high containment systems and can achieve containment to nanograms level. We have business units and distributors across the world to easily assist our global customer base.
Visit PSL at P-MEC Europe stand 40H59 to see the GFD Isolator. www.powdersystems.com
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.